A detailed history of Atticus Wealth Management, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Atticus Wealth Management, LLC holds 2 shares of BNTX stock, worth $253. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 2 -0.0%
Holding current value
$253
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

SELL
$98.5 - $125.08 $1,674 - $2,126
-17 Reduced 89.47%
2 $0
Q4 2022

Jan 31, 2023

SELL
$118.43 - $186.05 $118 - $186
-1 Reduced 5.0%
19 $2,000
Q4 2021

Jan 26, 2022

SELL
$216.64 - $362.52 $1,949 - $3,262
-9 Reduced 31.03%
20 $5,000
Q3 2021

Nov 09, 2021

BUY
$205.93 - $447.23 $411 - $894
2 Added 7.41%
29 $8,000
Q3 2021

Oct 18, 2021

BUY
$205.93 - $447.23 $5,560 - $12,075
27 New
27 $7,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $30.8B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Atticus Wealth Management, LLC Portfolio

Follow Atticus Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atticus Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atticus Wealth Management, LLC with notifications on news.